Home > News > Starpharma Pooled Development - half year report and accounts
February 25th, 2004
Starpharma Pooled Development - half year report and accounts
The results for the half year include a 42% reduction in the operating loss of the economic entity during the period, compared with the corresponding period of the previous year. Whilst part of this improvement has resulted from the successful conversion of the former controlled entity Dendritic Nanotechnologies Ltd to a US incorporated associated entity (Dendritic Nanotechnologies, Inc), two thirds of the savings are attributable to reductions in expenditure by the Australian group, as set out in the report.
Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014
Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014
Nanometrics Reports Second Quarter 2014 Financial Results July 30th, 2014
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014